Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 40.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 117,415 shares of the company's stock after selling 81,095 shares during the quarter. Russell Investments Group Ltd. owned about 0.12% of Intellia Therapeutics worth $1,369,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of NTLA. Franklin Resources Inc. lifted its position in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after buying an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock worth $157,000 after purchasing an additional 1,582 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after buying an additional 1,615 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of Intellia Therapeutics by 10.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock worth $210,000 after purchasing an additional 1,634 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after buying an additional 2,059 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Truist Financial lowered their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Wedbush reiterated a "neutral" rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Citigroup increased their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $36.68.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded down $0.21 during trading on Wednesday, reaching $8.11. The stock had a trading volume of 2,562,048 shares, compared to its average volume of 2,369,772. The stock has a market cap of $839.01 million, a PE ratio of -1.49 and a beta of 2.23. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The business has a fifty day moving average price of $8.83 and a 200-day moving average price of $12.01.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.